SHPHF (Sihuan Pharmaceutical Holdings Group) WACC %:-0.01% (As of Jun. 28, 2026)


SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
51 GF Score
Price $0.13
GF Value $0.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group WACC %?

Sihuan Pharmaceutical Holdings Group SHPHF 51 WACC % is -0.01% as of Jun. 28, 2026. GuruFocus rates SHPHF with a GF Score™ of 51/100 and a GF Value™ of $0.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,017 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks worse than 74.34% on this metric.

As of today (2026-06-28), Sihuan Pharmaceutical Holdings Group's weighted average cost of capital is -0.01%%. Sihuan Pharmaceutical Holdings Group's ROIC % is 2.48% (calculated using TTM income statement data). Sihuan Pharmaceutical Holdings Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

For a comprehensive WACC calculation, please access the WACC Calculator.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sihuan Pharmaceutical Holdings Group's weighted average cost of capital is -0.01%%. Sihuan Pharmaceutical Holdings Group's ROIC % is 2.48% (calculated using TTM income statement data). Sihuan Pharmaceutical Holdings Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Sihuan Pharmaceutical Holdings Group WACC % Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group WACC % Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.56 14.07 14.63 13.06 9.60

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.63 13.25 13.06 11.53 9.60

SHPHF vs ZTS: WACC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group WACC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's WACC % distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's WACC % falls into.


SHPHF
51GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Sihuan Pharmaceutical Holdings Group's market capitalization (E) is $955.040 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Sihuan Pharmaceutical Holdings Group's latest one-year semi-annual average Book Value of Debt (D) is $136.842 Mil.
a) weight of equity = E / (E + D) = 955.040 / (955.040 + 136.842) = 0.8747
b) weight of debt = D / (E + D) = 136.842 / (955.040 + 136.842) = 0.1253

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.376%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Sihuan Pharmaceutical Holdings Group's beta is -0.9509.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.376% + -0.9509 * 6% = -1.3294%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, Sihuan Pharmaceutical Holdings Group's interest expense (positive number) was $28.335 Mil. Its total Book Value of Debt (D) is $136.842 Mil.
Cost of Debt = 28.335 / 136.842 = 20.7064%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 32.658 / 58.802 = 55.54%.

Sihuan Pharmaceutical Holdings Group's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.8747*-1.3294%+0.1253*20.7064%*(1 - 55.54%)
=-0.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of -0.01% mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a WACC % of -0.01% as of Jun. 28, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. Over the past decade, Sihuan Pharmaceutical Holdings Group's WACC % has ranged from 3.95 to 14.63. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #756 out of 1017 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is Sihuan Pharmaceutical Holdings Group's WACC % too high?
Sihuan Pharmaceutical Holdings Group's current WACC % is -0.01%. Over the past 10 years, this metric has ranged from a low of 3.95 to a high of 14.63. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #756 out of 1017 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's WACC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #756 out of 1017 companies for WACC %. This places Sihuan Pharmaceutical Holdings Group in the lower half of its industry. The industry median WACC % is 8.86. Historically, Sihuan Pharmaceutical Holdings Group's own WACC % has ranged from 3.95 to 14.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.86, based on 1,017 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current WACC % is -0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.18, compared to a current price of $0.13 — trading 27.9% below its estimated fair value. The current WACC % is -0.01%. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current WACC % is -0.01% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.13 is trading 27.9% below its estimated GF Value™ of $0.18. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • WACC %: -0.01%
  • GF Value™: $0.18 vs. price of $0.13 (27.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
51GF Score

Get the complete analysis for SHPHF

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.18
GF Value